1. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics.10th ed. New York: McGraw-Hill; 2001.p.569-619.
2. Karami M, Zarrindast MR. Morphine sex-dependently induced place conditioning in adult Wistar rats. Eur J Pharmacol 2008; 582:78-87.
3. McClung CA. The molecular mechanisms of morphine addiction. Rev Neurosci 2006; 17: 393-402.
4. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M. Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Jpn J Pharmacol 2002; 88: 399-406.
5. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M. Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Sychopharmacol (Berl) 2003; 170: 80-88.
6. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 2007; 56:27-78.
7. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999; 22:521-527.
8. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998; 51:13-22.
9 Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13:185-193.
10. Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 2000; 153:31-43.
13. Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007; 12:227-462.
14. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56:613-72.
15. Vargas-Perez H, Ting-A-Kee R, van der Kooy D. Different neural systems mediate morphine reward and its spontaneous withdrawal aversion. Eur J Neurosci 2009; 29:2029-2034.
16. Wise RA. The role of reward pathways in the development of drug dependence. Pharmacol Ther 1987: 35:227- 263.
17. Zarrindast MR, Karami M, Sepehri H, Sahraei H. Influence of nitric oxide on morphine-induced conditioned place preference in the rat central amygdala. Eur J Pharmacol 2002; 453: 81-89.
18. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its anti-nociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc Natl Acad Sci USA 1995; 92:10540-10544.
19. Wang H-Y, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu-opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005; 135:247-261.
20. Zheng-xiong XI, Stein EA. Gabaergic mechanisms of opiate reinforcement. Alcohol 2002; 37:485-494.
21. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85:5274-5278.
22. Olmstead MC, Franklin KB. Development of a conditioned place preference: effects of lesions of various CNS sites. Behav Neurosci 1997; 111:1313-23.
23. Neisewander JL, Pierce RC, Bardo MT. Naloxone enhances the expression of morphine-induced conditioned place preference. Psychopharmacology (Berl) 1990; 100:201-205.
24. Diaz SL, Barros VG, Antonelli MC, Rubio MC, Balerio GN. Morphine withdrawal syndrome and its prevention with baclofen: Autoradiographic study of mu-opioid receptors in prepubertal male and female mice. Synapse 2006; 60:132-140.
26. Fukuto JM, Mayer B. The enzymology of nitric oxide synthase. In: Feelisch M, Stamler JS, editors. Methods in nitric oxide research. New York: John Wiley & Sons Ltd; 1996. p. 147-157.
27. Garthwaite J. Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 1991; 14:60-67.
28. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-142.
29. Kivastik T, Rutkauskaite J, Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Pharmacol Biochem Behav 1996; 53:1013-1015.
30. Paxinos G, Watson CR. The Rat Brain in Stereotaxic Coordinates. 5th ed. San Diego: Elsevier Academic Press; 2005.
31. Haghparast A, Azizi P, Hassanpour-Ezatti M, Khorrami H, Naderi N. Sub-chronic administration of AM251, CB1 receptor antagonist, within the nucleus accumbens induced sensitization to morphine in the rat. Neurosci Lett 2009; 467:43-47.
32. Karami M, Zarrindast MR, Sepehri H, Sahraei H. Role of nitric oxide in the rat hippocampal CA1 area on morphine-induced conditioned place preference . Eur J Pharmacol 2002; 449: 113-9.
33. Moaddab M, Haghparast A, Hassanpour-Ezatti M. Effects of reversible inactivation of the ventral tegmental area on the acquisition and expression of morphine-induced conditioned place preference in the rat. Behav Brain Res 2009; 198:466-471.
34. Overton DA. State-dependent learning produced by addicting drugs. In: Fisher S, Freedman, AM, editors. Opiate addiction: origin and treatments. Washington DC: Winston; 1973. p. 61-75.
35. Bie B, Zhu W, Pan ZZ. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. J Pharmacol Exp Ther 2009; 329:290-296.
36. Heinmiller A, Ting-A-Kee R, Vargas-Perez H, Yeh A, van der Kooy D. Tegmental pedunculopontine glutamate and GABA-B synapses mediate morphine reward. Behav Neurosci 2009; 123:145-155.
37. Skoubis PD, Matthes HW, Walwyn WM, Kieffer BL, Maidment NT. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice. Neuroscience 2001; 106:757-763.
38. Phillips AG, Le Paine FG. Reward produced by microinjection of (D-Ala2), Met5-enkephaline into the ventral tegmental area. Behav Brain Res 1982; 5:225-229.
39. Bozarth MA. Conditioned place preference. A parametric analysis using systemic heroin injections. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer- Verlag;1987.p.241-273.
40. Mucha RF, van der Kooy D, O'Shaughnessy M, Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res 1982; 243:91-105.
41. Mucha RF, Iversen SD. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology (Berl) 1984; 82:241-247.
42. Zarrindast MR, Faraji N, Rostami P, Sahraei H, Ghoshouni H. Cross tolerance between morphine- and nicotineinduced conditioned place preferences in mic. Pharmacol Biochem Behav 2003; 74:363-369.
43. Schulteis C, Morse AC, Liu J. Repeated experience with naloxone facilitates acute morphine withdrawal: potential role for conditioning processes in acute opioid dependence. Pharmacol Biochem Behav 2003; 76:493- 503.
44. Narita M, Funada M, Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 2001; 89:1-15.
45. Le Guen S, Gestreau C, Besson JM. Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system. Eur J Neurosci 2003; 17:2425-2437.
46. Skoubis PD, Matthes HW, Walwyn WM, Kieffer BL, Maidment NT. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice. Neurosci. 2001; 106:757-63.
47. Ishida S, Shimosaka R, Kawasaki Y, Jin C, Kitamura Y, Araki H, et al. Involvement of the amygdala on place aversion induced by naloxone in single-dose morphine-treated rats. Yakugaku Zasshi (in Japanese) 2008; 128:395-403.
48. Cabral A, Ruggiero RN, Nobre MJ, Brandão ML, Castilho VM. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:334-344.
49. Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Sensitization to the rewarding effects of morphine depends on dopamine. Neuroreport 2005; 16:201-205.
50. Rezayof A, Zarrindast MR, Sahraei H, Haeri-Rohani A. Involvement of dopamine receptors of the dorsal hippocampus on the acquisition and expression of morphine-induced place preference in rats. J Psychopharmacol 2003; 17:415-423.
51. Chelarescu D, Nechifor M. The method of conditioned place preference in pharmaco-dependence research. Rev Med Chir Soc Med Nat Iasi (in Romanian) 2005; 109:355-359.